Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04785976
Other study ID # KY 2020-11-26
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 1, 2012
Est. completion date April 1, 2032

Study information

Verified date November 2023
Source Beijing Tiantan Hospital
Contact Runting Li, MD
Phone +8615753166690
Email 1011168227@qq.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Rupture of intracranial aneurysms can lead to extensive subarachnoid hemorrhage (SAH), a potentially fatal neurological emergency with mortality rates ranging from 8 to 67%. At present, surgical clipping (SC) and endovascular coiling (EC) are two main treatments for aneurysmal subarachnoid hemorrhage (aSAH), in recent years, the improvements in surgical equipment and techniques have already greatly improved the postoperative safety of patients. However, considering individual differences between patients, some still at risk due to possible complications during hospitalization or after discharge from the hospital, it will no doubt generate a large healthcare burden. This prospective, observational clinical trial (LongTEAM) is to improve the diagnosis and treatment effect and efficiency in this field, reducing mortality, medical costs, and medical burden, while opening up new avenues for interdisciplinary clinical practice and scientific research exploration.


Recruitment information / eligibility

Status Recruiting
Enrollment 5000
Est. completion date April 1, 2032
Est. primary completion date March 1, 2032
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - All patients admitted to the emergency department of the investigator with aneurysmal subarachnoid hemorrhage are included in their prospective registry. Exclusion Criteria: - None

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Surgical clipping and endovascular coiling
Surgical clipping: Apply aneurysm clip to clip the ruptured aneurysm. Endovascular coiling:Also called endovascular embolization, to block blood flow into an aneurysm.Preventing blood flow into an aneurysm helps to keep it from rupturing.

Locations

Country Name City State
China Beijing Tiantan Hospital Beijing Beijing
China The First People's Hospital of Neijiang Neijiang Sichuan

Sponsors (2)

Lead Sponsor Collaborator
Beijing Tiantan Hospital Peking University International Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Unfavorable neurological outcome (mRS>2) Number of patients experiencing a unfavorable neurological outcome at discharge, defined as a modified Rankin Scale (mRS) score of >2. 10 days after the procedure
Primary Unfavorable neurological outcome (mRS>2) Number of patients experiencing a unfavorable neurological outcome at 3 months post-treatment, defined as a modified Rankin Scale (mRS) score of >2. 3 months
Primary Unfavorable neurological outcome (mRS>2) Number of patients experiencing a unfavorable neurological outcome at 6 months post-treatment, defined as a modified Rankin Scale (mRS) score of >2. 6 months
Primary Unfavorable neurological outcome (mRS>2) Number of patients experiencing a unfavorable neurological outcome at 12 months post-treatment, defined as a modified Rankin Scale (mRS) score of >2. 12 months
Primary Unfavorable neurological outcome (mRS>2) Number of patients experiencing a unfavorable neurological outcome at 24 months post-treatment, defined as a modified Rankin Scale (mRS) score of >2. 24 months
Secondary Cognitive deficits Number of patients experiencing a unfavorable neurological outcome at discharge,defined as changes in thinking, emotion, will and behavior. 10 days after the procedure
Secondary Cognitive deficits Number of patients experiencing a unfavorable neurological outcome at 3 months, defined as changes in thinking, emotion, will and behavior. 3 months
Secondary Cognitive deficits Number of patients experiencing a unfavorable neurological outcome at 6 months, defined as changes in thinking, emotion, will and behavior. 6 months
Secondary Cognitive deficits Number of patients experiencing a unfavorable neurological outcome at 12 months, defined as changes in thinking, emotion, will and behavior. 12 months
Secondary Cognitive deficits Number of patients experiencing a unfavorable neurological outcome at 24 months, defined as changes in thinking, emotion, will and behavior. 24 months
Secondary Major adverse cardiac or cerebrovascular events Number of patients experiencing an event including all-cause death, non-fatal cerebrovascular event, non-fatal any myocardial infarction and revascularization at discharge. 10 days after the procedure
Secondary Major adverse cardiac or cerebrovascular events Number of patients experiencing an event including all-cause death, non-fatal cerebrovascular event, non-fatal any myocardial infarction and revascularization at 3 months. 3 months
Secondary Major adverse cardiac or cerebrovascular events Number of patients experiencing an event including all-cause death, non-fatal cerebrovascular event, non-fatal any myocardial infarction and revascularization at 6 months. 6 months
Secondary Major adverse cardiac or cerebrovascular events Number of patients experiencing an event including all-cause death, non-fatal cerebrovascular event, non-fatal any myocardial infarction and revascularization at 12 months. 12 months
Secondary Major adverse cardiac or cerebrovascular events Number of patients experiencing an event including all-cause death, non-fatal cerebrovascular event, non-fatal any myocardial infarction and revascularization at 24 months. 24 months
See also
  Status Clinical Trial Phase
Completed NCT03209830 - Pharmaceutical Treatment of Fatigue After Aneurysmal Subarachnoid Hemorrhage Phase 2
Completed NCT05131295 - Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage. Phase 3
Recruiting NCT04583163 - Variability in Transcranial Doppler Technique in Neuro-Critical Care Patients
Not yet recruiting NCT03271697 - Astragalus Membranaceus on Aneurysmal Subarachnoid Hemorrhage Phase 2/Phase 3
Recruiting NCT01098890 - Intraventricular Tissue Plasminogen Activator (tPA) in the Management of Aneurysmal Subarachnoid Hemorrhage Phase 2
Completed NCT00692744 - Quality of Life in Elderly After Aneurysmal Subarachnoid Hemorrhage (SAH) N/A
Active, not recruiting NCT05738083 - Prediction Models for Complications, Disability, and Death in Patients With Aneurysmal Subarachnoid Hemorrhage
Completed NCT03754335 - SubArachnoid Hemorrhage HEadache Treated by Lumbar Puncture N/A
Completed NCT06076590 - Impact of Multiple Electrolytes Injection Ⅱ and Saline on Hyperchloremia in Patients With Aneurysmal Subarachnoid Hemorrhage:a Pilot Study Phase 4
Recruiting NCT04548401 - Effect of Antiplatelet Therapy on Cognition After Aneurysmal Subarachnoid Hemorrhage
Terminated NCT04148105 - Cilostazol and Nimodipine Combined Therapy After Aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 4
Recruiting NCT06329635 - Treatment of Vasospasm of Aneurysmal Subarachnoid Hemorrhage With Intrathecal Nicardipine - FAST-IT Trial N/A
Recruiting NCT02129413 - Safety Study of Carotid Body Neurostimulation to Treat Cerebral Vasospasm N/A
Terminated NCT00487461 - Use of Simvastatin for the Prevention of Vasospasm in Aneurysmal Subarachnoid Hemorrhage N/A
Recruiting NCT06288659 - aSAH Treatment Based on Intraventricular ICP Monitoring: A Prospective, Multicenter, Randomized and Controlled Trial N/A
Recruiting NCT05974111 - COAgulation Disorders in Ischaemic and Haemorrhagic Stroke
Recruiting NCT03706768 - Degradation of the Glycocalyx in Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage N/A
Recruiting NCT06284642 - Early Lumbar Drainage Combined With Intrathecal Urokinase Injection for Treatment of Severe Aneurysmal SAH (LD-ITUK) Phase 4
Recruiting NCT01773200 - Prognostic Value of Circulating Endothelial Progenitor Cells in Aneurysmal Subarachnoid Hemorrhage N/A
Completed NCT02026596 - SpareBrain - Mechanisms and Prevention of Secondary Brain Injury in Subarachnoid Haemorrhage N/A